Disclaimer: This article is intended as policy analysis and advocacy content for a general audience. It does not constitute individual medical advice. People with health concerns should consult a qualified healthcare professional.
A System Built Without Women in Mind
For most of the twentieth century, clinical medicine operated on a foundational assumption that went largely unexamined: the male body was the default. Drug trials enrolled male participants-often exclusively-on the rationale that female hormonal cycles introduced confounding variables. Cardiovascular disease was studied in men. Dosing thresholds were calibrated to average male physiology. Pain scales were validated on male cohorts.
The downstream consequences of that assumption are still being paid by Australian women today. Conditions that disproportionately or exclusively affect women are diagnosed late, treated inadequately, or funded at levels that bear no relationship to their burden on the population. This is not an historical curiosity. It is a live policy failure with measurable costs: in quality of life, in workforce participation, in healthcare expenditure, and in preventable deaths.
Australia has made incremental progress-a National Women's Health Strategy, targeted PBS listings, expanded telehealth access. But incremental progress against a structural deficit produces structural results. Closing the women's health funding gap requires confronting the architecture of underinvestment, not simply adding line items to existing programs.
The Research Foundation Problem
The United States National Institutes of Health (NIH) did not mandate the inclusion of women in federally funded clinical research until 1993, under the NIH Revitalization Act. Before that legislative intervention, most phase III trials were conducted exclusively or predominantly in male populations. Australia had no equivalent legislative mandate and no equivalent policy moment. The Medical Research Future Fund (MRFF) and the National Health and Medical Research Council (NHMRC) have both moved toward requiring sex-disaggregated reporting in grant applications, but implementation has been inconsistent, and enforcement mechanisms remain weak.
The NHMRC's own data illustrates the gap clearly. Women's health conditions-defined narrowly to include reproductive and gynaecological conditions rather than the broader burden of sex-influenced disease-receive funding that is substantially lower per disability-adjusted life year (DALY) than men's health conditions at comparable burden levels. Endometriosis alone affects approximately 830,000 Australian women, generates an estimated $9.7 billion annually in healthcare costs and lost productivity, yet for decades received research funding in the low millions per year. By contrast, prostate cancer-with a comparable prevalence in its eligible population-has benefited from dedicated research centres, consumer advocacy infrastructure, and sustained NHMRC and MRFF investment.
This is not a criticism of prostate cancer funding. It is an observation that the political economy of health research reflects the historical gender composition of research institutions, funding bodies, and clinical leadership-and that correcting it requires explicit intervention, not market equilibration.
Endometriosis: A Diagnostic Crisis in Plain Sight
Endometriosis is a condition in which tissue similar to the uterine lining grows outside the uterus, typically on the ovaries, fallopian tubes, and the tissue lining the pelvis. It causes chronic pelvic pain, dysmenorrhoea, dyspareunia, bowel and bladder symptoms, and infertility. It affects approximately 1 in 9 Australian women of reproductive age-around 830,000 people.
The average diagnostic delay in Australia is between 6.5 and 10 years from symptom onset to confirmed diagnosis. In some regional and rural settings, the delay is longer. This figure has not materially improved over the past two decades despite growing clinical awareness and a 2018 National Action Plan for Endometriosis.
The reasons for the delay are structural rather than individual. Endometriosis symptoms are normalised-by clinicians, by cultural scripts about menstruation, and by the women experiencing them who have been told that severe period pain is ordinary. Definitive diagnosis historically required laparoscopic surgery, creating an access bottleneck: surgical waitlists, out-of-pocket costs, and the requirement for a referral pathway that presupposes a GP who takes the presenting symptoms seriously.
Medicare's coverage of gynaecological specialist consultations is inadequate. Bulk-billing gynaecologists are rare in major metropolitan areas and essentially absent in regional and remote Australia. A woman in rural New South Wales or Queensland presenting with pelvic pain faces a referral to a specialist she may wait months to see, pay several hundred dollars out of pocket to consult, and who may then recommend a surgical procedure on a further waitlist. The financial and geographic barriers compound the clinical barriers, and the diagnostic clock keeps running.
The 2018 National Action Plan committed to improving GP education, expanding awareness campaigns, and developing clinical guidelines. These were worthwhile commitments. But they did not address the economic architecture of specialist access. Subsidising GP awareness does not help when the follow-on referral pathway remains financially prohibitive. Funding awareness campaigns does not reduce the out-of-pocket cost of a gynaecology consultation that Medicare rebates at a fraction of actual fees.
Australia has a successful model for delivering specialist care at scale: the comprehensive cancer centre network. Multidisciplinary, publicly funded, with co-located diagnostics, surgical, and medical oncology capacity. There is no structural reason this model cannot be applied to endometriosis. Dedicated endometriosis and pelvic pain centres-announced in the 2023 federal budget-represent a step in this direction, but the funded rollout needs to prioritise underserved geographic areas and ensure genuine bulk-billing access rather than nominal availability.
The Autoimmune Burden: A Women's Health Crisis Without a Ribbon
Approximately 80 percent of autoimmune disease patients are women. The conditions in this category are diverse-systemic lupus erythematosus (SLE), Hashimoto's thyroiditis, multiple sclerosis (MS), rheumatoid arthritis, Sjögren's syndrome, primary biliary cholangitis-but they share a common epidemiological profile: predominantly female, frequently under-recognised in early stages, and associated with substantial diagnostic delays.
Lupus affects an estimated 20,000 Australians, with women comprising around 90 percent of cases. The average time from symptom onset to diagnosis for lupus in Australia is approximately five years. Hashimoto's thyroiditis is the most common cause of hypothyroidism in Australia; its early-stage presentation as fatigue, cognitive dulling, mood disturbance, and weight changes is frequently attributed to lifestyle factors, anxiety, or depression before thyroid function is systematically investigated. MS, which affects women at roughly three times the rate of men in Australia, is increasingly understood to have a pre-clinical inflammatory phase where earlier intervention may alter long-term trajectory-but early diagnosis requires clinical suspicion that is not uniformly present across the GP workforce.
The research funding picture for autoimmune conditions mirrors the pattern seen in endometriosis. Conditions with a predominantly female burden receive less research investment relative to their disease burden than conditions with a more sex-balanced or predominantly male burden. The NHMRC has acknowledged this disparity in strategic planning documents but has not yet implemented a systematic funding correction mechanism.
There is an additional layer of complexity: the intersection of autoimmune disease with other under-researched women's health areas. Autoimmune flares are frequently triggered or worsened by hormonal transitions-menarche, pregnancy, the perimenopause. Research into these interactions is sparse. Clinicians managing lupus or MS in perimenopausal women are often working without evidence-based guidance on how hormonal management interacts with immunosuppressive therapy or disease activity. This is not a clinical failure-it is a research funding failure that places clinicians in an evidence vacuum.
Menopause: The Treatment Gap That Guidelines Alone Cannot Close
Menopausal hormone therapy (MHT) underwent a severe setback in public and clinical perception following the 2002 Women's Health Initiative (WHI) study, which reported increased risks of breast cancer, cardiovascular events, and stroke in a study population that was, on average, 63 years old-well past the window in which MHT provides its primary benefits. The nuanced re-analysis of WHI data, which demonstrated that these risks were substantially reduced or absent in women who initiated MHT close to menopause onset (the "timing hypothesis" or "window of opportunity"), took years to penetrate GP training and practice.
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) updated its position statement to reflect the current evidence-that MHT is safe and appropriate for most symptomatic women under 60 or within ten years of menopause onset, with individualised risk assessment-but the gap between guideline and practice remains significant. Survey data from Australian GP cohorts consistently shows that MHT prescribing rates are lower than evidence would support, that GP confidence in MHT counselling is variable, and that women are frequently left managing vasomotor symptoms, genitourinary syndrome, sleep disruption, and mood disturbance without access to evidence-based treatment.
The consequences extend beyond symptom burden. Estrogen has documented protective effects on bone density, cardiovascular health, and cognitive function. Women who are denied appropriate MHT counselling during the perimenopause-or who are discouraged from it by clinicians whose risk-benefit framing is anchored in the pre-re-analysis WHI interpretation-may face accelerated bone loss, increased cardiovascular risk, and quality of life degradation that could have been mitigated.
Rural and regional access compounds the problem. Gynaecologists and menopause specialists are concentrated in metropolitan areas. The bulk-billing gap means that women outside major cities who need specialist menopause management face the same financial and geographic barriers as those seeking endometriosis care. Telehealth has partially addressed this-and its permanency for specialist consultations is therefore not merely a convenience issue but a women's health equity issue. See our analysis of telehealth permanency advocacy for the broader policy case. The specific policy gaps and reform requirements for menopause care are examined in our analysis of menopause healthcare reform in Australia.
The Structural Reforms Australia Needs
The evidence base for reform is not in dispute. The policy mechanisms exist. What has been lacking is the political prioritisation required to move from acknowledgment to implementation. The following reforms address the structural causes of the women's health funding gap rather than its symptoms.
Mandatory sex-disaggregated reporting in clinical trials. All NHMRC and MRFF-funded research involving human participants should be required to enrol and report findings by sex, with analysis of sex-specific outcomes as a condition of funding. This brings Australia into line with international best practice and begins to repair the evidentiary deficit that underlies clinical under-treatment.
Dedicated endometriosis specialist centres with genuine bulk-billing access. The announced endometriosis centre funding must be implemented with geographic equity criteria and binding bulk-billing requirements. Co-location of imaging, specialist consultation, surgical booking, and allied health (pelvic physiotherapy, pain psychology) is essential-a dispersed referral chain does not serve patients with a six-to-ten year diagnostic history of fragmented care.
Mandatory MHT education updates for GP re-credentialing. Given the documented gap between RANZCOG guidelines and actual prescribing, GP re-credentialing should require updated training on menopause management that reflects post-WHI evidence. This is achievable within existing continuing professional development frameworks and does not require legislative change-only Royal Australian College of General Practitioners (RACGP) policy decision.
Telehealth permanency for women's health specialist consultations. Temporary telehealth provisions introduced during the COVID-19 pandemic substantially improved access to gynaecology, endocrinology, and menopause specialist consultations for rural and regional women. Making these provisions permanent is a low-cost, high-impact reform that directly addresses geographic inequity in specialist access. The rural and remote health access challenges documented elsewhere on this site are directly relevant here.
Revised Medicare rebate schedule for gynaecological consultations. The current Medicare rebate for specialist gynaecology consultations has not kept pace with actual consultation costs, driving the shift toward private billing and out-of-pocket fees that exclude lower-income patients. A targeted rebate review, with priority for long-consultation items relevant to complex conditions like endometriosis and autoimmune disease, would improve access without requiring the creation of new program infrastructure.
NHMRC research funding floor for sex-influenced disease burden. The NHMRC should implement a minimum funding floor tied to DALY burden for conditions that disproportionately affect women, with a review mechanism every three years. This does not reduce funding for other conditions-it ensures that growing research investment is distributed in proportion to actual disease burden rather than historical advocacy momentum.
These recommendations do not exist in isolation. The bulk-billing crisis has particular relevance to women's health access, because the collapse of bulk-billing in specialist practice disproportionately affects those who require recurrent specialist management of chronic conditions-a category in which women are overrepresented.
Conclusion: Equity Is Not a Supplement to Health Policy
The framing of women's health as a niche or special-interest area of health policy has outlived whatever justification it once had. Women constitute slightly more than half the Australian population. The conditions that disproportionately affect them-endometriosis, autoimmune disease, menopause-related morbidity, reproductive health disorders-generate billions of dollars in healthcare costs and lost productivity annually. The research underfunding that drives diagnostic delays and treatment gaps is not a women's issue; it is a national health system efficiency issue that affects the entire economy.
Closing the funding gap does not require choosing between women's health and other health priorities. It requires applying the same logic of evidence-based resource allocation to conditions that affect women as is already applied to conditions that have historically attracted stronger research and advocacy investment. The tools-NHMRC funding mechanisms, Medicare schedule reform, GP training infrastructure, telehealth policy-are already in place. What is required is the political will to use them proportionately.
The Coalition for Better Health will continue to advocate for the structural reforms outlined here, with particular focus on the implementation of dedicated endometriosis specialist centres, mandatory sex-disaggregated clinical trial reporting, and telehealth permanency as foundational steps toward genuine gender health equity in Australia.
This analysis draws on publicly available NHMRC funding data, Australian Institute of Health and Welfare (AIHW) disease burden statistics, Endometriosis Australia prevalence data, and published clinical literature on menopausal hormone therapy and autoimmune disease epidemiology.